Twist Bioscience (NASDAQ:TWST) Trading 6.9% Higher - Time to Buy?

Key Points

• Twist Bioscience Corporation's share price rose 6.9% to $33.27 during mid-day trading, despite trading volume dropping significantly to 145,316 shares.
• A consensus rating of "Moderate Buy" has been established for TWST, with a target price of $48.50, according to nine equities research analysts.
• In its latest earnings report, Twist Bioscience reported a loss of ($0.47) EPS, exceeding expectations, with revenues of $96.06 million.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s share price traded up 6.9% during mid-day trading on Wednesday . The stock traded as high as $32.59 and last traded at $33.27. 145,316 shares were traded during trading, a decline of 88% from the average session volume of 1,260,984 shares. The stock had previously closed at $31.12.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TWST. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Barclays cut their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a report on Thursday, October 2nd. Evercore ISI decreased their price target on shares of Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a report on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.

Twist Bioscience Price Performance

The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -23.21 and a beta of 2.38. The company has a 50 day simple moving average of $27.76 and a 200-day simple moving average of $32.84.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Activity

In related news, CEO Emily M. Leproust sold 2,265 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 5,987 shares of company stock worth $158,202 in the last ninety days. 3.01% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TWST. GAMMA Investing LLC grew its holdings in shares of Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after buying an additional 303 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 15.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Twist Bioscience during the second quarter valued at approximately $97,000. Bayforest Capital Ltd boosted its position in Twist Bioscience by 49.3% during the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after purchasing an additional 1,604 shares during the last quarter. Finally, Pallas Capital Advisors LLC acquired a new position in Twist Bioscience during the first quarter valued at approximately $201,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.